The UK, EU4 and emerging markets across eastern Europe present a major opportunity for U.S. biotechnology companies. However, many such companies decide to license their products to partner companies, assuming that launching in Europe is complex. The result: Often, the product fails to achieve its full value. To be globally competitive, EVERSANA can work with you to assess and adapt your development and commercialization strategies to retain the value of your product.
Europe Is Complex, but Not Complicated
Europe is a highly diverse market that provides significant opportunity for any company seeking to globalize its products. With a greater understanding of the region and the individual countries’ nuances, companies can make more informed choices, secure better deal terms with partners and explore their commercialization options. Unlike other markets, regulatory approval, price, reimbursement and access are all intimately linked in Europe. Most countries will not enter reimbursement, access or pricing discussions if a company has not begun the application process for marketing authorization or has one already.
Launch Sequence Matters
Countries are increasingly interconnected, with decisions taken in one market having a ripple effect across the globe. Traditional approaches to launch sequencing need re-evaluation due to multiple changes occurring across the globe. The wrong decision can impact revenue for the lifetime of your product.
European Commercial Readiness Opportunity Assessment
Powered by our proprietary, best-in-class price and access platform Pricentric® by EVERSANA, the European Commercial Readiness Opportunity Assessment helps companies assess their opportunity in Europe. Our team of experts will partner with you to ensure that you have the information you need to maximize your revenue potential.
Is this the right strategy for my product?
Schedule a complimentary 30-minute session to learn more.
For the first time, the European Union is undergoing a major overhaul of its pharmaceutical industry with the new Pharmaceutical Strategy for Europe, which was launched in late 2020. Through this strategy, the European Union (EU) is making changes to its infrastructure with the goal of building a holistic, patient-centered, forward-looking pharmaceutical landscape for all EU member […]
The globe is facing a multitude of governing and legislative changes that will directly affect pharma and pricing in coming years, with many of these changes initiated by the pandemic. As countries become increasingly interconnected, decisions in one pharmaceutical market will have ripple effects globally.